Psychopharmacology and Psychiatry Updates Beyond Standard Treatment: Exploring Pramipexole in Bipolar Depression
Feb 15, 2026
Kristin Raj, M.D., psychiatrist and clinical faculty known for practical psychopharmacology guidance. She discusses why a dopamine agonist like pramipexole might help treatment‑resistant bipolar depression. The conversation covers the PAX‑BD trial design, 12‑ and 36‑week results, safety concerns like hypomania and impulse control, and practical monitoring and dosing considerations.
AI Snips
Chapters
Transcript
Episode notes
Typical Treatment-Resistant Case
- A 42-year-old woman with bipolar II cycled through depressive episodes despite multiple trials of quetiapine, lamotrigine, and lorazidone.
- She remained symptomatic on lithium, illustrating a typical treatment-resistant bipolar depression case.
Dopamine Targeting Rationale
- Pramipexole targets hypodopaminergic mechanisms in bipolar depression via D3 agonism and may increase hippocampal neurogenesis.
- Prior small trials showed benefit, providing a mechanistic and empirical rationale for larger testing.
Pragmatic Definition Of Resistance
- Treatment-resistant bipolar depression was defined pragmatically as failure, intolerance, or refusal of two recommended agents.
- This highlights the scale of unmet need, as many patients remain depressed long-term despite standard options.